Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16
The DOI matches its Crossref record; 26 of the 28 references it cites were found in a registry or an index.
Abstract
D-type cyclins, in association with the cyclin-dependent kinases Cdk4 or Cdk6, promote progression through the G1 phase of the cell cycle by phosphorylating the retinoblastoma protein (RB). The activities of Cdk4 and Cdk6 are constrained by inhibitors such as p16, the product of the CDKN2 gene on human chromosome 9p21 (refs 12-14). The frequent deletion or mutation of CDKN2 in tumour cells suggests that p16 acts as a tumour suppressor. We show that wild-type p16 arrests normal diploid cells in late G1, whereas a tumour-associated mutant of p16 does not. Significantly, the ability of p16 to induce cell-cycle arrest is lost in cells lacking functional RB, including primary fibroblasts from Rb-/- mouse embryos. Thus, loss of p16, overexpression of D-cyclins and loss of RB have similar effects on G1 progression, and may represent a common pathway to tumorigenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Importantly, cells lacking functional RB were resistant to p16INK4a-mediated cell cycle arrest, implying that the ability of CDK4 (and later, CDK6) to drive G1 phase progression required RB (33-35) and predicting that chemical CDK4/6 inhibitors would show efficacy only if RB were functionally intact.”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [33]
Citations
Cites
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
A cell cycle regulator potentially involved in genesis of many tumor types
Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., & Skolnick, M. H. (1994) · Science · doi:10.1126/science.8153634 · Cited by 2,751
G1 phase progression: Cycling on cue
Sherr, C. J. (1994) · Cell · doi:10.1016/0092-8674(94)90540-1 · Cited by 2,674
Cyclins and cancer II: Cyclin D and CDK inhibitors come of age
Hunter, T., & Pines, J. (1994) · Cell · doi:10.1016/0092-8674(94)90543-6 · Cited by 2,091
pl5INK4B is a potentia| effector of TGF-β-induced cell cycle arrest
Hannon, G. J., & Beach, D. (1994) · Nature · doi:10.1038/371257a0 · Cited by 1,950
Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers
Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K., & Carson, D. A. (1994) · Nature · doi:10.1038/368753a0 · Cited by 1,742
Cyclin D1 is a nuclear protein required for cell cycle progression in G1
Baldin, V, Lukas, J., Marcote, M. J., Pagano, M., & Draetta, G. (1993) · Genes & Development · doi:10.1101/gad.7.5.812 · Cited by 1,614
Self-citation(1993) · Genes & Development · doi:10.1101/gad.7.3.331 · Cited by 1,264
Distinct Roles for Cyclin-Dependent Kinases in Cell Cycle Control
van den Heuvel, S., & Harlow, E. (1993) · Science · doi:10.1126/science.8266103 · Cited by 1,092
Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts.
Quelle, D. E., Ashmun, R. A., Shurtleff, S. A., Kato, J. Y., Bar-Sagi, D., Roussel, M. F., & Sherr, C. J. (1993) · Genes & Development · doi:10.1101/gad.7.8.1559 · Cited by 1,032
Research works printed but not linked: 8
- Jiang, W. et al. Oncogene 8, 3447–3457 (1993).
- Lukas, J., Pagano, M., Staskova, Z., Draetta, G. & Bartek, J. Oncogene 9, 707–718 (1994).
- Jen, J. et al. Cancer Res. 54, 6353–6358 (1994).
- Li, Y., Nichols, M. A., Shay, J. W. & Xiong, Y. Cancer Res. 54, 6078–6082 (1994).
- Otterson, G. A., Kratzke, R. A., Coxon, A., Kim, Y. W. & Kaye, F. J. Oncogene 9, 3375–3378 (1994).
- Tam, S. W. Shay, J. W. & Pagano, M. Cancer Res. 54, 5816–5820 (1994).
- Ohta, M. et al. Cancer Res. 54, 5269–5272 (1994).
- Lukas, J. et al. Oncogene (in the press).
Cited by
Items 201–300 of 902
Hui, R., Macmillan, R. D., Kenny, F. S., Musgrove, E. A., Blamey, R. W., Nicholson, R. I., Robertson, J. F. R., & Sutherland, R. L. (2000) · PubMed · Cited by 143
Cell Cycle–Targeted Cancer Therapies
Sherr, C. J., & Bártek, J. (2016) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-040716-075628 · Cited by 130
“Because the final target of the pathway is RB itself, p16INK4a arrests RBproficient cells during G1 but lacks activity in that subset of tumor cells that are RB deficient (Koh et al. 1995, Lukas et al. 1995, Medema et al. 1995).”
BackgroundpRb and p16 protein alterations in human oral tumorigenesis
Pande, P. K., Mathur, M., Shukla, N. K., & Ralhan, R. (1998) · Oral Oncology · doi:10.1016/s1368-8375(98)00024-4 · Cited by 136
Cyclin E, a redundant cyclin in breast cancer
Gray-Bablin, J., Zalvide, J. B., Fox, M., Knickerbocker, C. J., DeCaprio, J. A., & Keyomarsi, K. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.26.15215 · Cited by 129
Genomic alterations in spontaneous and carcinogen-induced murine melanoma cell lines
Melnikova, V. O., Bolshakov, S. V., Walker, C., & Ananthaswamy, H. N. (2004) · Oncogene · doi:10.1038/sj.onc.1207405 · Cited by 132
“…transcription factor E2F1 by nonphosphorylated retinoblastoma-susceptibility (pRb) tumor suppressor protein (Serrano et al., 1993; Koh et al., 1995; Lukas et al., 1995). p14ARF mediates G1 and G2 arrests by binding to human double minute protein 2 (HDM2, mouse Mdm2) and blocking HDM2-induced…”
Backgroundlin-35Rb andcki-1Cip/Kip cooperate in developmental regulation of G1 progression inC. elegans
Boxem, M., & van den Heuvel, S. (2001) · Development · doi:10.1242/dev.128.21.4349 · Cited by 141
“Indirect evidence in support of an essential role has been provided by overexpressing the CDK4/6 inhibitor p16INK4A (Bruce et al., 2000; Koh et al., 1995; Lukas et al., 1995; Medema et al., 1995).”
BackgroundIsolation and characterization of p19INK4d, a p16-related inhibitor specific to CDK6 and CDK4.
Guan, K. L., Jenkins, C. W., Li, Y., O'Keefe, C. L., Noh, S., Wu, X., Zariwala, M., Matera, A. G., & Xiong, Y. (1996) · Molecular Biology of the Cell · doi:10.1091/mbc.7.1.57 · Cited by 118
Mortier, L., Marchetti, P., Delaporte, E., de Lassale, E. M., Thomas, P., Piette, F., Formstecher, P., Polakowska, R. R., & Danzé, P.-M. (2002) · Cancer Letters · doi:10.1016/s0304-3835(01)00757-1 · Cited by 135
Cdk6–cyclin D3 activity in murine ES cells is resistant to inhibition by p16INK4a
Faast, R., White, J., Cartwright, P., Crocker, L. A., Šarčević, B., & Dalton, S. (2004) · Oncogene · doi:10.1038/sj.onc.1207133 · Cited by 126
“Stable expression of p16INK4a in ES cells A non-Cdk-binding mutant of p16 (p16P114L; Koh et al., 1995; Lukas et al., 1995) was generated using QuikChange sitedirected mutagenesis (Stratagene). p16 and pl6P114L were cloned as XhoI fragments into pCAGiP (Pratt et al., 2000), such that their…”
MethodGius, D. R., Ezhevsky, S. A., Becker‐Hapak, M., Nagahara, H., Wei, M. C., & Dowdy, S. F. (1999) · PubMed · Cited by 116
Hangaishi, A., Ogawa, S., Imamura, N., Miyawaki, S., Miura, Y., Uike, N., Shimazaki, C., Emi, N., Takeyama, K., Hirosawa, S., et al. (1996) · Blood · doi:10.1182/blood.v87.12.4949.bloodjournal87124949 · Cited by 115
Combinatorial roles for pRB, p107, and p130 in E2F-mediated cell cycle control
Classon, M., Salama, S., Gorka, C., Mulloy, R., Braun, P., & Harlow, E. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.190343497 · Cited by 115
A question of balance: the role of cyclin-kinase inhibitors in development and tumorigenesis
Elledge, S. J., Winston, J. T., & Harper, J. W. (1996) · Trends in Cell Biology · doi:10.1016/0962-8924(96)10030-1 · Cited by 120
Expression of INK4 inhibitors of cyclin D-dependent kinases during mouse brain development.
Zindy, F., Soares, H. D., Herzog, K., Morgan, J., Sherr, C. J., & Roussel, M. F. (1997) · PubMed · Cited by 140
Honma, T., Yoshizumi, T., Hashimoto, N., Hayashi, K., Kawanishi, N., Fukasawa, K., Takaki, T., Ikeura, C., Ikuta, M., Suzuki‐Takahashi, I., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010326y · Cited by 120
Radkov, S. A., Bain, M., Farrell, P. J., West, M. J., Rowe, M., & Allday, M. J. (1997) · Journal of Virology · doi:10.1128/jvi.71.11.8552-8562.1997 · Cited by 113
“The SmaI restriction fragments containing the EBNA3C cDNA were blunt end ligated into the BglII site of the pSG5 vector. pGAL4-EBNA3Caa11-992D207-368 was constructed by transferring the EcoRV fragment from pSG5-EBNA3CD207-368 which spans the deletion, into pGAL4-EBNA3Caa11-992. pSG5-EBNA3C-Jk (M) was constructed by re…”
BackgroundInfluentialRequirement of Cyclin E-Cdk2 Inhibition in p16 INK4a -Mediated Growth Suppression
Jiang, H., Chou, H. S., & Zhu, L. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.9.5284 · Cited by 113
Cell Cycle and Biochemical Effects of PD 0183812
Fry, D. W., Bedford, D. C., Harvey, P. H., Fritsch, A., Keller, P. R., Wu, Z., Dobrusin, E., Leopold, W. R., Fattaey, A., & Garrett, M. D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008867200 · Cited by 108
Induction of p16 during immortalization by HPV 16 and 18 and not during malignant transformation
Nakao, Y., Yang, X., Yokoyama, M., Ferenczy, A. S., Tang, S.-C., Pater, M. M., & Pater, A. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.243 · Cited by 123
“Other labels are described in the text p16 functions as a negative regulator of the cell cycle in the presence of wild-type Rb through the pl6/cdk-cyclin/Rb cascade (Guan et al, 1994; Lukas et al, 1995).”
BackgroundPathogenetic mechanisms in gastric cancer
Shi, J., Qu, Y.-P., & Hou, P. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i38.13804 · Cited by 125
Manne, U., Myers, R. B., Moron, C., Poczatek, R. B., Dillard, S. C., Weiss, H. L., Brown, D., Srivastava, S., & Grizzle, W. E. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970620)74:3<296::aid-ijc11>3.0.co;2-a · Cited by 163
Proteomic Identification of a Direct Role for Cyclin D1 in DNA Damage Repair
Jirawatnotai, S., Hu, Y., Livingston, D. M., & Sicinski, P. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3549 · Cited by 104
“cancer cells, which do not require cyclin D1 for proliferation (46, 47).”
Gorospe, M., Liu, Y., Xu, Q., Chrest, F. J., & Holbrook, N. J. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.3.762 · Cited by 111
“The growing number of CKIs includes p16 (Ink4/Mts1) (31), p14/p15 (Ink4B/Mts2) (11, 13), p18 (11), p27 (Kip1, p28) (16, 44, 52), p19 (56), p57 (Kip2) (28, 34), and the above-mentioned p21 (Waf1/Cip1/ Sdi1).”
ResultE2F4 Is Exported from the Nucleus in a CRM1-Dependent Manner
Gaubatz, S., Lees, J. A., Lindeman, G. J., & Livingston, D. M. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.4.1384-1392.2001 · Cited by 106
Functional analysis of pRb2/p130 interaction with cyclins.
Claudio, P. P., Luca, A. D., Howard, C. M., Baldi, A., Firpo, E. J., Koff, A., Paggi, M. G., & Giordano, A. (1996) · PubMed · Cited by 123
Mælandsmo, G., Flørenes, V., Hovig, E., Øyjord, T., Engebraaten, O., Holm, R., Børresen, A.-L., & Fodstad, Ø. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.181 · Cited by 106
Ct, L., Capodieci, P., Osman, I., Fazzari, M. J., Ferrara, J., Scher, H. I., & Cordon‐Cardo, C. (1999) · PubMed · Cited by 111
Development of the Ocular Lens
(2004) · Cambridge University Press eBooks · doi:10.1017/cbo9780511529825 · Cited by 123
Sørensen, C. S., Lukas, C., Kramer, E. R., Peters, J.-M., Bartek, J., & Lukas, J. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.20.7613-7623.2000 · Cited by 104
“Immunoprecipitation, immunoblotting, and in situ immunocytochemical techniques including detection of bromodeoxyuridine (BrdU) incorporated into newly synthesized DNA were described earlier (33, 35 ).”
MethodSelf-citationRegulation of CDK4 activity by a novel CDK4-binding protein, p34SEI-1
Sugimoto, M., Nakamura, T., Ohtani, N., Hampson, L., HAMPSON, I. N., Shimamoto, A., Furuichi, Y., Okumura, K., Niwa, S., Taya, Y., et al. (1999) · Genes & Development · doi:10.1101/gad.13.22.3027 · Cited by 122
Bond, J. A., Haughton, M. F., Rowson, J. M., Smith, P. J., Gire, V., Wynford-Thomas, D., & Wyllie, F. S. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.4.3103 · Cited by 104
Cell cycle regulators: mechanisms and their role in aetiology, prognosis, and treatment of cancer.
Michalides, R. J. A. M. (1999) · Journal of Clinical Pathology · doi:10.1136/jcp.52.8.555 · Cited by 114
Phosphorylation‐dependent and ‐independent functions of p130 cooperate to evoke a sustained G1 block
Hansen, K. H., Farkas, T., Lukas, J., Holm, K., Rönnstrand, L., & Bartek, J. (2001) · The EMBO Journal · doi:10.1093/emboj/20.3.422 · Cited by 111
Self-citationTakino, H., Li, C., Hu, S., Kuo, T., Geissinger, E., Müller‐Hermelink, H. K., Kim, B.-C., Swerdlow, S. H., & Inagaki, H. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.159 · Cited by 103
Frequent overexpression of the cyclin D1 oncogene in invasive lobular carcinoma of the breast.
Oyama, T., Kashiwabara, K., Yoshimoto, K., Arnold, A., & Koerner, F. (1998) · PubMed · Cited by 113
Gorgoulis, V. G., Zacharatos, P., Kotsinas, A., Liloglou, T., Kyroudi, A., Veslemes, M., Rassidakis, A., Halazonetis, T. D., Field, J. K., & Kittas, C. N. (1998) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65690-8 · Cited by 113
Role of cyclooxygenase-2 in gastric cancer development and progression
Cheng, J., & Fan, X.-M. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i42.7361 · Cited by 100
Role of pRB dephosphorylation in cell cycle regulation
Tamrakar, S. (2000) · Frontiers in Bioscience · doi:10.2741/tamrakar · Cited by 101
Role of Cyclin-Dependent Kinases and Their Inhibitors in Cellular Differentiation and Development
Chellappan, S., Giordano, A., & Fisher, P. B. (1998) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-71941-7_4 · Cited by 102
p16 and p16 beta are potent growth suppressors of head and neck squamous carcinoma cells in vitro.
Liggett, W. H., Sewell, D. A., Rocco, J., Ahrendt, S. A., Koch, W. M., & Sidransky, D. (1996) · PubMed · Cited by 114
Alteration of pRb/p16/cdk4 regulation in human osteosarcoma
Benassi, M. S., Molendini, L., Gamberi, G., Ragazzini, P., Sollazzo, M. R., Merli, M., Asp, J., Magagnoli, G., Balladelli, A., Bertoni, F., et al. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19991022)84:5<489::aid-ijc7>3.0.co;2-d · Cited by 115
Selective In Vivo and In Vitro Effects of a Small Molecule Inhibitor of Cyclin-Dependent Kinase 4
Soni, R., O'Reilly, T., Furet, P., Muller, L., Stephan, C., Zumstein-Mecker, S., Fretz, H., Fabbro, D., & Chaudhuri, B. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.6.436 · Cited by 97
“hereafter referred to as p16, which acts by binding to Cdk4 and preventing its association with cyclin D1 as well as the subsequent phosphorylation of pRb (6, 11 ,12).”
BackgroundFunctional Mechanisms for Human Tumor Suppressors
Sun, W., & Yang, J. P. (2010) · Journal of Cancer · doi:10.7150/jca.1.136 · Cited by 115
“The tumor suppressors that adopt this mechanism include retinoblastoma protein (Rb), adenomatosis polyposis coli (APC), alternate reading frame (ARF), RIZ1, p15, p16, p18, p19, p21, p27, and p53 (8, 9, 11-21).”
BackgroundIncreased histone H1 phosphorylation and relaxed chromatin structure in Rb-deficient fibroblasts.
Herrera, R. E., Chen, F., & Weinberg, R. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11510 · Cited by 98
Khanna, C., Anderson, P. M., Hasz, D. E., Katsanis, E., Neville, M., & Klausner, J. S. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970401)79:7 · Cited by 561
Rambau, P., Vierkant, R. A., Intermaggio, M. P., Kelemen, L. E., Goodman, M. T., Herpel, E., Pharoah, P. D. P., Kommoss, S., Jimenez‐Liñan, M., Karlan, B. Y., et al. (2018) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.109 · Cited by 113
“p14 inhibits p53 function and p16 inhibits the CDK4/6 complex acting as a negative cell cycle regulator suppressing the transition from the Gap1 to DNA synthesis (G1/S) phase and arresting the cell cycle in the G1 phase [2].”
BackgroundArresting developments in the cardiac myocyte cell cycle: Role of cyclin-dependent kinase inhibitors
Brooks, G., Poolman, R. A., & Li, J. M. (1998) · Cardiovascular Research · doi:10.1016/s0008-6363(98)00125-4 · Cited by 113
Saab, R. H., Bills, J. L., Miceli, A. P., Anderson, C., Khoury, J. D., Fry, D. W., Navid, F., Houghton, P. J., & Skapek, S. X. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0383 · Cited by 96
Acute lymphoblastic leukemia in adolescents and young adults in Finland
Usvasalo, A., Räty, R., Knuutila, S., Vettenranta, K. K., Harila‐Saari, A. H., Jantunen, E., Kauppila, M., Koistinen, P., Parto, K., Riikonen, P. V., et al. (2008) · Haematologica · doi:10.3324/haematol.12466 · Cited by 98
Constitutively active protein phosphatase 1α causes Rb-dependent G1 arrest in human cancer cells
Berndt, N., Dohadwala, M., & Liu, C. W. Y. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00185-0 · Cited by 107
Ultraviolet radiation induces p16CDKN2A expression in human skin.
Pavey, S. J., Conroy, S., Russell, T., & Gabrielli, B. G. (1999) · PubMed · Cited by 117
Kim, K. S., Sack, J. S., Tokarski, J. S., Qian, L., Chao, S. T., Leith, L. W., Kelly, Y. F., Misra, R. N., Hunt, J. T., Kimball, S. D., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000231g · Cited by 104
Aberrant Cyclin D1 splicing in cancer: from molecular mechanism to therapeutic modulation
Wang, J., Su, W., Zhang, T., Zhang, S., Lei, H., Ma, F., Shi, M., Shi, W., Xie, X., & Di, C. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05763-7 · Cited by 101
Emadi‐Baygi, M., Soheili, Z., Schmitz, I., Sameie, S., & Schulz, W. A. (2010) · Cell Biology and Toxicology · doi:10.1007/s10565-010-9163-5 · Cited by 93
“Introduction of p16 induces cell cycle arrest only in cells retaining functional pRb (Lukas et al. 1995).”
BackgroundMannhardt, B., WEINZIMER, S. A., Wagner, M., Fiedler, M., Cohen, P., Jansen‐Dürr, P., & Zwerschke, W. (2000) · Molecular and Cellular Biology · doi:10.1128/.20.17.6483-6495.2000 · Cited by 94
Oppenheimer, C. W., Blalock, W. L., Steelman, L. S., Chang, F., & McCubrey, J. A. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(00)00085-1 · Cited by 102
Temperature-Sensitive Mutants of p16CDKN2 Associated with Familial Melanoma
Parry, D., & Peters, G. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.7.3844 · Cited by 94
“Several groups have tried to confirm the role of p16 as a tumor suppressor by demonstrating that tumor-specific mutations in p16 affect its function (27, 30, 45, 46, 59, 61).”
BackgroundInfluentialSelf-citationDai, C. Y., Furth, E. E., Mick, R., Koh, J., Takayama, T., Niitsu, Y., & Enders, G. H. (2000) · Gastroenterology · doi:10.1053/gast.2000.17952 · Cited by 92
Zwerschke, W., & Jansen‐Dürr, P. (1999) · Advances in cancer research · doi:10.1016/s0065-230x(08)61022-2 · Cited by 109
Protein arginine methylation: an emerging regulator of the cell cycle
Raposo, A. E., & Piller, S. C. (2018) · Cell Division · doi:10.1186/s13008-018-0036-2 · Cited by 100
RB/E2F1 as a Master Regulator of Cancer Cell Metabolism in Advanced Disease
Mandigo, A. C., Yuan, W., Xu, K., Gallagher, P., Pang, A., Guan, Y. F., Shafi, A. A., Thangavel, C., Sheehan, B., Bogdan, D., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1114 · Cited by 91
Role of p16/MTS1, cyclin D1 and RB in primary oral cancer and oral cancer cell lines
Sartor, M., Steingrimsdottir, H., Elamin, F., Gäken, J. A., Warnakulasuriya, S., Partridge, M., Thakker, N., Johnson, N. W., & Tavassoli, M. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690505 · Cited by 103
Retinoblastoma Tumor Suppressor Targets dNTP Metabolism to Regulate DNA Replication
Angus, S. P., Wheeler, L. J., Ranmal, S. A., Zhang, X., Markey, M. P., Mathews, C. K., & Knudsen, E. S. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205911200 · Cited by 85
Alterations in the INK4a/ARF locus and their effects on the growth of human osteosarcoma cell lines
Park, Y.-B., Park, M. J., Kimura, K., Shimizu, K., Lee, S. H., & Yokota, J. (2002) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(01)00575-1 · Cited by 100
Jones, C. J., Kipling, D., Morris, M., Hepburn, P., Skinner, J., Bounacer, A., Wyllie, F. S., Ivan, M., Bartek, J., Wynford-Thomas, D., et al. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.15.5690-5699.2000 · Cited by 89
“For p16ink4a, monolayers were fixed in acetone-methanol, 1:1 (10 min at 220°C), and a standard indirect immunoperoxidase procedure applied, using mouse monoclonal antibody DCS-50 (43) (Oncogene Research Products), followed by peroxidase-conjugated rabbit anti-mouse immunoglobulin (Ig) (Dako).”
MethodInfluentialMatrix metalloproteinases in tumour invasion and metastasis
Curran, S., & Murray, G. I. (1999) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199911)189:3<358::aid-path452>3.0.co;2-1 · Cited by 661
Boland, J. M., McPhail, E. D., García, J. J., Lewis, J. E., & Schembri‐Wismayer, D. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.186 · Cited by 89
“6 which is thought to cause p16 (cyclin-dependent kinase inhibitor 2A, CDKN2A ) overexpression by functional inactivation of the retinoblastoma protein”
BackgroundSerological evidence of an association betweenChlamydia pneumoniae infection and lung cancer
Laurila, A. L., Anttila, T., Läärä, E., Bloigu, A., Virtamo, J., Albanes, D., Leinonen, M., & Saikku, P. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970220)74:1<31::aid-ijc6>3.0.co;2-1 · Cited by 138
Kato, D., Miyazawa, K., Ruas, M., Starborg, M., Wada, I., Oka, T., Sakai, T., Peters, G., & Hara, E. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)00426-8 · Cited by 87
Self-citationRamalingam, A., Hirai, A. M., & Thompson, E. A. (1997) · Molecular Endocrinology · doi:10.1210/mend.11.5.9923 · Cited by 96
CDKN2A (p16INK4A) somatic and germline mutations
Smith-Sørensen, B., & Hovig, E. (1996) · Human Mutation · doi:10.1002/(sici)1098-1004(1996)7:4<294::aid-humu2>3.0.co;2-9 · Cited by 87
Dong, Y., Sui, L., Sugimoto, K., Tai, Y., & Tokuda, M. (2001) · International Journal of Cancer · doi:10.1002/1097-0215(20010720)95:4<209::aid-ijc1036>3.0.co;2-r · Cited by 93
Calbó, J., Parreño, M., Sotillo, E., Yong, T., Mazo, A., Garriga, J., & Graña, X. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m209181200 · Cited by 94
Schang, L. M., Hossain, A., & Jones, C. (1996) · Journal of Virology · doi:10.1128/jvi.70.6.3807-3814.1996 · Cited by 93
“Flat-cell analysis was performed as described previously (10, 20, 37).”
BackgroundMethodKelly, B. L., Wolfe, K. G., & Roberts, J. M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.5.2535 · Cited by 102
Fuxe, J., Akusjärvi, G., Goike, H. M., Roos, G., Collins, V. P., & Pettersson, R. F. (2000) · PubMed · Cited by 99
Vidal, A., Millard, S. S., Miller, J. P., & Koff, A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m112090200 · Cited by 83
The role of transforming growth factor Β in glioma progression
Jennings, M. T., & Pietenpol, J. A. (1998) · Journal of Neuro-Oncology · doi:10.1023/a:1005863419880 · Cited by 99
INK4 cell cycle inhibitors direct transcriptional inactivation of NF-κB
Wolff, B., & Naumann, M. (1999) · Oncogene · doi:10.1038/sj.onc.1202617 · Cited by 85
“…(reviewed in Luque and Gelinas, 1997), likewise frequent genetic alterations and functional inhibition of p16 in human tumors (Kamb et al., 1994; Lukas et al., 1995) and especially in pancreatic tumors (Caldas et al., 1994; Naumann et al., 1996) have suggested that its inactivation can…”
BackgroundLeng, X., Noble, M. E. M., Adams, P. D., Qin, J., & Harper, J. W. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.7.2242-2254.2002 · Cited by 91
“Until recently, it was thought that the major, if not exclusive substrate of cyclin D1/Cdk4 was Rb ( 40 , 45).”
BackgroundPhelps, D. E., Hsiao, K.-M., Li, Y., Hu, N., Franklin, D. S., Westphal, E., Lee, E. Y.-H. P., & Xiong, Y. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.4.2334 · Cited by 86
Akt-Mediated Phosphorylation of XLF Impairs Non-Homologous End-Joining DNA Repair
Liu, P., Gan, W., Guo, C., Xie, A., Gao, D., Guo, J., Zhang, J., Willis, N. A., Su, A., Asara, J. M., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.01.005 · Cited by 91
“However, under this experimental condition, we found that DR-U2OS cells could not be fully arrested in G0/ G1 in part due to the compromised p14Arf/p16INK4a tumor suppressor pathways (Guan et al., 1994; Lukas et al., 1995; Stott et al., 1998).”
BackgroundLeone, G., DeGregori, J., Jakoi, L., Cook, J. G., & Nevins, J. R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.12.6626 · Cited by 83
Aberrations of the G1- and G1/S-regulating genes in human cancer
Bártková, J., Lukas, J., & Bártek, J. (1997) · Springer eBooks · doi:10.1007/978-1-4615-5371-7_16 · Cited by 100
Self-citationAllelic deletion at chromosome 9p21(p16) and 17p13(p53) in microdissected sporadic dysplastic nevus
Park, W., Vortmeyer, A. O., Pack, S., Duray, P. H., Böni, R., Guerami, A. A., Emmert‐Buck, M. R., Liotta, L. A., & Zhuang, Z. (1998) · Human Pathology · doi:10.1016/s0046-8177(98)90221-0 · Cited by 87
Molecular Genetics of Head and Neck Cancer
Gleich, L. L., & Salamone, F. N. (2002) · Cancer Control · doi:10.1177/107327480200900502 · Cited by 97
Nitta, R. T., Jameson, S. A., Kudlow, B. A., Conlan, L. A., & Kennedy, B. K. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.02464-05 · Cited by 84
Impact ofIGF-IandCYP19Gene Polymorphisms on the Survival of Patients With Metastatic Prostate Cancer
Tsuchiya, N., Wang, L., Suzuki, H., Segawa, T., Fukuda, H., Narita, S., Shimbo, M., Kamoto, T., Mitsumori, K., Ichikawa, T., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.9439 · Cited by 81
Increased risk of prostate cancer associated with AA genotype of cyclin D1 gene A870G polymorphism
Wang, L., Habuchi, T., Mitsumori, K., Li, Z., Kamoto, T., Kinoshita, H., Tsuchiya, N., Sato, K., Οhyama, C., Nakamura, A., et al. (2002) · International Journal of Cancer · doi:10.1002/ijc.10793 · Cited by 81
The INK4A/ARF Locus: Role in Cell Cycle Control and Apoptosis and Implications for Glioma Growth
Ivanchuk, S. M., Mondal, S., Dirks, P. B., & Rutka, J. T. (2001) · Journal of Neuro-Oncology · doi:10.1023/a:1010632309113 · Cited by 93
Thullberg, M., Bártková, J., Khan, S., Hansen, K. H., Rönnstrand, L., Lukas, J., Strauss, M., & Bartek, J. J. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01307-7 · Cited by 87
Self-citationInvolvement of cyclin D activity in left ventricle hypertrophy in vivo and in vitro
Busk, P. K. (2002) · Cardiovascular Research · doi:10.1016/s0008-6363(02)00510-2 · Cited by 80
Wianny, F., Real, F. X., Mummery, C. L., van Rooijen, M. A., Lahti, J. M., Samarut, J., & Savatier, P. (1998) · Developmental Dynamics · doi:10.1002/(sici)1097-0177(199805)212:1<49::aid-aja5>3.0.co;2-2 · Cited by 99
Frequent mutations of CDKN2 in primary pancreatic adenocarcinomas
Bartsch, D., Shevlin, D. W., Tung, W. S., Kisker, O., Wells, S. A., & Goodfellow, P. J. (1995) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.2870140306 · Cited by 79
Mateos, M., García‐Sánz, R., López‐Pérez, R., Moro, M. J., Ocio, E. M., Hernández‐Rivas, J., Megido, M., Caballero, M. D., Fernández‐Calvo, J., Bárez, A., et al. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03749.x · Cited by 86
“…Journal of Haematology, 2002, 118, 1034–1040 1034 2002 Blackwell Science Ltd blocks the cell cycle progression through its binding to either cyclin-dependent kinase (CDK) 4 or CDK6, preventing the ligation between these CDKs and cyclin D (Hirama & Koeffler, 1995; Lukas et al, 1995).”
BackgroundHuman papillomavirus in high- and low-risk areas of oesophageal squamous cell carcinoma in China
Shuyama, K., Castillo, A., Aguayo, F., Sun, Q., Khan, N., Koriyama, C., & Akiba, S. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603765 · Cited by 79
“Note, however, that p16INK4a is frequently inactivated through hypermethylation of p16INK4a promoter and through deletion at near-p16 loci (Serrano et al, 1993; Xing et al, 1999; Tokunaga et al, 2002).”
BackgroundMolecular biology of adenoid cystic carcinoma
Liu, J., Shao, C., Tan, M., Mu, D., Ferris, R. L., & Ha, P. K. (2011) · Head & Neck · doi:10.1002/hed.21849 · Cited by 80
Role of tumor suppressor genes in the development of adult T cell leukemia/lymphoma (ATLL)
Hatta, Y., & Koeffler, H. (2002) · Leukemia · doi:10.1038/sj.leu.2402458 · Cited by 90
Mechanism of Retinoblastoma Gene Inactivation in the Spectrum of Neuroendocrine Lung Tumors
Gouyer, V., Gazzéri, S., Bolon, I., Drevet, C., Brambilla, C., & Brambilla, E. (1998) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.18.2.3008 · Cited by 78
“Both p16 INK4 inactivation (22) and cyclin D1 overexpression (23) are responsible for RB metabolic inactivation.”
BackgroundRestoration of retinoblastoma mediated signaling to Cdk2 results in cell cycle arrest
Strobeck, M. W., Fribourg, A. F., Puga, A., & Knudsen, E. S. (2000) · Oncogene · doi:10.1038/sj.onc.1203510 · Cited by 88
“It is believed that the Cyclin D/Cdk4 complex acts principally to phosphorylate RB, since the Cyclin D/Cdk4 inhibitor, p16ink4a, or injection of anti-Cyclin D antibodies does not inhibit cell cycle progression in RB de®cient cells (Koh et al., 1995; Lukas et al., 1995a,b; Medema et al., 1995).”
Background
Metadata
- Authors
- Lukas, J., Parry, D., Aagaard, L., Mann, D. J., Bartkova, J., Strauss, M., Peters, G., & Bartek, J.
- Affiliations
- Danish Cancer Society (DK)
- ORCID
- Mann, David J.
- Venue
- Nature
- Published
- 1995-06
- Volume
- 375
- Issue
- 6531
- Pages
- 503-506
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2010493387
- Cited by
- 899
- References
- 28
- Citations by year
- 2026: 9 · 2025: 6 · 2024: 6 · 2023: 7 · 2022: 16 · 2021: 15 · 2020: 14 · 2019: 15 · 2018: 17 · 2017: 16 · 2016: 15 · 2015: 15 · 2014: 14 · 2013: 22 · 2012: 16
- FWCI
- 32.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Ophthalmology › Ocular Oncology and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
- Keywords
- p16, retinoblastoma protein, CDKN2, tumour suppressor, cell cycle arrest, G1 phase progression, D-type cyclins, CDK4, CDK6, retinoblastoma, carcinogenesis, chromosome 9p21
- MeSH terms
- Animals, Carrier Proteins, Cell Cycle, Cells, Cultured, Cloning, Molecular, Escherichia coli, Humans, Mice, Inbred BALB C, Microinjections, Mutation, Proto-Oncogene Proteins, Recombinant Proteins, Tumor Cells, Cultured, Oncogene Proteins, Genes, Tumor Suppressor, Retinoblastoma Protein, G1 Phase, Cyclins, Protein Serine-Threonine Kinases, Cyclin-Dependent Kinases, Cyclin D1, Cyclin-Dependent Kinase Inhibitor p16, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.